29 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 29 separate news trends connected to Pharmaceutical Industry, spanning June 30, 2026 through October 27, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 243 article observations and 229 source signals, led by Business, Health, World coverage. Use it to compare how individual events emerged, spread and changed over time.
Missouri Attorney General sends cease-and-desist letter to Eli Lilly over drug pricing policy.
Novo's next-generation obesity drug surprises with 25% weight loss in women, despite demand concerns.
Free meals and perks from Big Pharma sway doctors' prescribing habits, a review of 93 studies finds.
Trump Administration Finalizes Plan to Lower Drug Prices in Medicare
Former House majority leader Eric Cantor jumps to the top of pharma lobbying as PhRMA’s new CEO, turning Capitol experience into industry muscle.
A $4 billion Merck‑Daiichi lung‑cancer partnership falters as the firms pull their FDA filing.
Exercise may match common pain medications, research finds.
7 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Novo Nordisk has signed an up to $1.4 billion licensing deal with Danish biotech Orbis Medicines to develop oral macrocycle drugs for cardiometabolic diseases.
7 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Novo Nordisk’s sudden halt of two heart‑failure trials slashes hopes for an IL‑6 drug and rattles investors.
Personalized mRNA cancer vaccines spark a biotech gold rush, drawing investors and reshaping oncology treatment.
Teva's experimental antibody TEV-408 hits a key phase IIa endpoint in celiac disease studies.
Novartis secures a high-stakes subcutaneous delivery agreement with Alteogen, shifting industry dynamics and drawing varied market reactions.
GSK's mRNA flu vaccine is advancing to Phase 3 trials after outperforming standard shots in Phase 2.
Eli Lilly's $2.88 billion acquisition of Merida Biosciences is poised to reshape the autoimmune disease treatment landscape.
11 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Roche’s $2.5 billion pact for Hanmi’s muscle‑sparing obesity drug ignites expectations for a new weight‑loss breakthrough
A new weight loss drug may burn fat without the muscle loss seen in GLP-1 drugs.
A cancer vaccine breakthrough is stirring debate over profits and public health, as Moderna and Merck's stock prices surge.
Novo Nordisk faces intensifying competition from Eli Lilly in the global GLP-1 weight-loss market as its early industry lead faces significant pressure.
Divergent earnings reports this week reveal a surge in pharmaceutical demand alongside cooling momentum in the digital advertising sector.
Eli Lilly is expanding access to its experimental obesity drug, Retatrutide, ahead of approval.
Two pharmaceutical giants are in merger talks, potentially reshaping the industry.
AstraZeneca and Bristol Myers Squibb are in talks for a $400bn merger, a deal that would reshape the pharmaceutical industry
Pharmaceutical and drug testing industries warn that President Trump's move to reschedule marijuana will lead to increased abuse.
The FDA has introduced a proposal to consolidate registration requirements for distributed drug manufacturing networks, aiming to increase supply chain transparency.
Anthropic's new AI platform, Claude Science, targets researchers and the pharmaceutical industry.